Targeted
Chelating Agents
/ adverse effects
Humans
Lead
Lead Radioisotopes
Neuroendocrine Tumors
/ diagnostic imaging
Octreotide
/ adverse effects
Organometallic Compounds
/ adverse effects
Positron-Emission Tomography
Radionuclide Imaging
Radiopharmaceuticals
/ adverse effects
Receptors, Somatostatin
Somatostatin
/ adverse effects
212Pb-DOTAMTATE
NEN
NET
PRRT
TAT
phase 1
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
15
09
2021
revised:
04
01
2022
pubmed:
8
1
2022
medline:
13
10
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
Peptide receptor radiotherapy with somatostatin analogs has been successfully used for years as a treatment for somatostatin-overexpressing tumors. Treatment of neuroendocrine tumors (NETs) with the β-particle emitter
Identifiants
pubmed: 34992153
pii: jnumed.121.263230
doi: 10.2967/jnumed.121.263230
pmc: PMC9454455
doi:
Substances chimiques
Chelating Agents
0
Lead Radioisotopes
0
Organometallic Compounds
0
Radiopharmaceuticals
0
Receptors, Somatostatin
0
copper dotatate CU-64
0
Lead
2P299V784P
Somatostatin
51110-01-1
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1326-1333Informations de copyright
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Target Oncol. 2018 Apr;13(2):189-203
pubmed: 29423595
Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1023-1031
pubmed: 31652074
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):934-946
pubmed: 31707430
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1802-11
pubmed: 27160225
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19
pubmed: 25273832
JAMA Oncol. 2018 Jun 1;4(6):874-876
pubmed: 29710201
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702
pubmed: 29891520
Int J Mol Sci. 2019 Jun 22;20(12):
pubmed: 31234481
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
J Nucl Med. 2011 Sep;52(9):1361-8
pubmed: 21795361
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):54-63
pubmed: 34448031
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
AJR Am J Roentgenol. 2018 Aug;211(2):278-285
pubmed: 29949416
Curr Med Chem. 2020;27(41):7003-7031
pubmed: 32720598
Pharmaceutics. 2020 Dec 31;13(1):
pubmed: 33396374
J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S
pubmed: 28864614